Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Enzon Pharma Inc (ENZN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTHER OTC]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTHER OTC]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 10,613
  • Shares Outstanding, K 44,220
  • Annual Sales, $ 8,380 K
  • Annual Income, $ -1,130 K
  • 36-Month Beta 1.11
  • Price/Sales 1.24
  • Price/Cash Flow 0.00
  • Price/Book 0.94
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 0.02
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 05/22/17
  • Annual Dividend & Yield 0.15 (64.10%)
  • Most Recent Dividend 0.30 on 12/13/16
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.2200 +9.09%
on 05/09/17
0.2596 -7.55%
on 05/23/17
-0.0044 (-1.80%)
since 04/26/17
3-Month
0.2200 +9.09%
on 05/09/17
0.3400 -29.41%
on 03/03/17
-0.0851 (-26.18%)
since 02/24/17
52-Week
0.2200 +9.09%
on 05/09/17
0.4990 -51.90%
on 11/30/16
-0.1580 (-39.70%)
since 05/26/16

Most Recent Stories

More News
Enzon Pharmaceuticals Partnering Deals and Alliances 2010 to 2017

SummaryThis report provides all the information you require to better understand Enzon Pharmaceuticals and its partnering interests and activities since 2010.

ENZN : 0.2400 (+2.56%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More

Support & Resistance

2nd Resistance Point 0.2579
1st Resistance Point 0.2490
Last Price 0.2400
1st Support Level 0.2321
2nd Support Level 0.2241

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.